← All Ac Immune SA filings

Ac Immune SA 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ACIU
Ac Immune SA
20-F: AC Immune Reports 2025 Losses Amid R&D Investment & Pipeline Progress
AC Immune SA reported a net loss of CHF 70.4 million for 2025, driven by significant R&D investments and strategic pipeline advancements in neurodegenerative diseases, while maintaining sufficient liquidity until Q3 2027.
NASDAQ
ACIU
Ac Immune SA
20-F: AC Immune SA Files 20-F Report for Fiscal Year 2024
AC Immune SA releases its annual report on Form 20-F, detailing the company's financial results and business activities for the year ended December 31, 2024.
NASDAQ
ACIU
Ac Immune SA
20-F: AC Immune SA Details Share Structure, Governance in Latest Filing
AC Immune SA outlines its share capital, corporate governance practices, and related information in its recent filing.